Lactate uptake through monocarboxylate transporter 1 (MCT1) is associated with aggressive disease in non-small cell lung cancer (NSCLC), but how lactate transport supports tumor metabolism remains incompletely understood. Integrating stable isotope tracing, metabolomics, and transcriptomics across patient tumors, anima...
Robert B. Cameron, Kristen E. Shema, Nathan Dubois et al.· bioRxiv· 0 citations
More than half of patients with early-stage non-small cell lung cancer (NSCLC) experience recurrent disease following definitive therapy. Targeted therapies have demonstrated significant and clinically meaningful benefit in EGFR-, ALK-, or RET-driven early-stage NSCLC. There are, however, no approved therapies for earl...
J. Chaft, Jay M. Lee, Suresh Senan et al.· Future Oncology· 0 citations
In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.
A. Prelaj, V. Mišković, Matteo Sacco et al.· Nature Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
